Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes.

Atsushi KitamuraMasafumi KurajohYuya MikiYoshinori KakutaniYuko YamazakiAkinobu OchiTomoaki MoriokaKatsuhito MoriTetsuo ShojiMasanori Emoto

Published in: Journal of diabetes investigation (2024)

The results of XOR inhibitor treatment, especially a sufficient reduction in serum uric acid level, may provide protective effects on insulin secretory capacity in patients with type 2 diabetes.

Keyphrases

uric acid
type diabetes
metabolic syndrome
glycemic control
skeletal muscle
smoking cessation